Clinical trial
Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque…
NCT00338754 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00338754 |
|---|---|
| Title | Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| Official title | A Phase 2/3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Efficacy and Safety of Adalimumab in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| Lead sponsor | Abbott, Industry |
| Collaborators | Eisai Limited Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks |
| Enrollment | 160 |
| Start date | Nov 1, 2005 |
| First posted | Jun 20, 2006 |
| Last update posted | Sep 11, 2007 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: